PRIOR INFORMATION NOTICE: Antithrombotic agents, blood substitutes and perfusion solutions and antihemorrhagics

Finnish Institute for Health and Welfare, later referred to as THL or Customer, is about to publish a call for tenders for "Antithrombotic agents, blood substitutes and perfusion solutions and antihemorrhagics". The date of publication of the call for tenders is planned for October 2024. The scope of procurement is described in more detail in Annex 1. The procurement will be divided in six (6) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots. LOT 1: Enoxaparin sodium 100 mg/ml (1 ml per vial/ampoule/prefilled syringe, ATC B01AB05) LOT 2: 5% glucose electrolyte solution (1000 ml, i.v. solution, ATC B05BB02) LOT 3: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule, ATC B05BB01) LOT 4: Ringer's solution (1000 ml, i.v. solution, ATC B05BB01) LOT 5: Freeze-dried plasma (200 ml, bottle, ATC B05AA) LOT 6: Tranexamic acid 100 mg/ml (10 ml per vial/ampoule, ATC B02AA02) The minimum requirements for the products is described in Annex 1.1. The contract will be awarded to one supplier for each lot based on a comparison of tenders. Estimated quantity for the products is described in Annex 1.2 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 1.2, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The supplier is not obliged to deliver the products under the Option. THL reserves the right to change the scope of the procurement and the minimum requirements in the published call for tenders.

The availability for the Annex 1.2 is restricted to security classification level IV (TL IV). THL will send the Annex 1.2 to a representative of the tenderer via encrypted e-mail after THL has received a scanned version of the signed confidentiality commitment (Annex 2). The signature of the confidentiality commitment shall be done manually by hand. Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the e-mail address kirjaamo@thl.fi with the subject line: "CONFIDENTIALITY COMMITMENT - THL/5607/2.02.06/2024 / Antithrombotic agents, blood substitutes and perfusion solutions and antihemorrhagics". The message shall contain name of the tenderer and e-mail address to which the Annex 1.2 is to be sent.